Diagnostic and Therapeutic Radiopharmaceutical Agents for Selective Discrimination of Prostate Cancer
Abstract
The project investigated the development of ligand linked Flutamide analogs for complexing a M(CO)3 (Re,99mTc) organometallic species to target prostate cancer for imaging and therapy. The project has been successful in developing and testing new synthetic strategies for this application. General methods were established for preparing the complexes in excellent yields(>95%) at (10-4,10-5 M) ligand concentration, testing the stability of the complexes (pH, temperature) and in vitro (serum, AR +/- prostate cancer cells). First generation 99mTc flutamide analogs were examined. The results indicated the complexes formed with tridentate ligands (i.e., cysteine, histidine) were successfully prepared and maintained stability. The "2+1" approach analogs were prepared, however, failed to maintain the complex conformation, when examined under biological conditions. Second generation and addition coordination modes are also being investigated.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2008
- Accession Number
- ADA499840
Entities
People
- Paul D Benny
Organizations
- Washington State University